1-amino-3-[(tert-butyldiphenylsilyl)oxy]propan-2-ol | 204977-67-3

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 1-amino-3-[(tert-butyldiphenylsilyl)oxy]propan-2-ol
• 英文别名: 1-Amino-3-[tert-butyl(diphenyl)silyl]oxypropan-2-ol；1-amino-3-[tert-butyl(diphenyl)silyl]oxypropan-2-ol
• CAS: 204977-67-3
• 化学式: C₁₉H₂₇NO₂Si
• 分子量: 329.514
• InChiKey: MQSKNUDYXKCYKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.88
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-amino-3-[(tert-butyldiphenylsilyl)oxy]propan-2-ol 在 碳酸氢钠 、 戴斯-马丁氧化剂 、 三乙胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 tert-butyl-diphenyl-[[7-chloro-6-(3-fluoro-2-pyridyl)-4-methyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-1-yl]methoxy]silane
  参考文献：
  名称：

  [EN] NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
  [FR] NOUVEAUX DÉRIVÉS DE BENZODIAZÉPINE COMME AGENTS PAM DE GABA A GAMMA1

  摘要：

  The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

  公开号：

  WO2023052312A1
• 作为产物：
  描述：

  tert-butyl(oxiran-2-ylmethoxy)diphenylsilane 在 甲醇 、 氨 作用下， 反应 48.0h， 以99%的产率得到1-amino-3-[(tert-butyldiphenylsilyl)oxy]propan-2-ol
  参考文献：
  名称：

  Du, Jinfa; Chu, Chung K., Nucleosides and Nucleotides, 1998, vol. 17, # 1-3, p. 1 - 13

  摘要：

  DOI：

文献信息

• Short Soluble Coumarin Crosslinkers for Light-Controlled Release of Cells and Proteins from Hydrogels
  作者：Caroline de Gracia Lux、Jacques Lux、Guillaume Collet、Sha He、Minnie Chan、Jason Olejniczak、Alexandra Foucault-Collet、Adah Almutairi

  DOI：10.1021/acs.biomac.5b00950

  日期：2015.10.12

  Materials that degrade or dissociate in response to low power light promise to enable on-demand, precisely localized delivery of drugs or bioactive molecules in living systems. Such applications remain elusive because few materials respond to wavelengths that appreciably penetrate tissues. The photocage bromohydroxycoumarin (Bhc) is efficiently cleaved upon low-power ultraviolet (UV) and near-infrared (NIR) irradiation through one- or two-photon excitation, respectively. We have designed and synthesized a short Bhc-bearing crosslinker to create light-degradable hydrogels and nanogels. Our crosslinker breaks by intramolecular cyclization in a manner inspired by the naturally occurring ornithine lactamization, in response to UV and NIR light, enabling rapid degradation of polyacrylamide gels and release of small hydrophilic payloads such as an ∼10 nm model protein and murine mesenchymal stem cells, with no background leakage.

  能够响应低功率光降解或解离的材料有望实现对药物或生物活性分子在活体系统中按需、精确的局部递送。然而，这类应用仍然难以实现，因为很少有材料能够响应足以穿透组织的波长。光笼溴羟基香豆素（Bhc）通过单光子或双光子激发，能够分别在低功率紫外线（UV）和近红外线（NIR）照射下有效裂解。我们设计并合成了一个含有Bhc的短链交联剂，以创建光可降解的水凝胶和纳米凝胶。我们的交联剂在UV和NIR光的激发下，通过内分子环化方式（灵感源自天然存在的鸟氨酸内酰胺化过程）发生断裂，从而实现聚丙烯酰胺凝胶的快速降解以及对小型亲水性载荷（如约10纳米大小的模型蛋白质和鼠源间充质干细胞）的释放，且无背景泄漏现象。
• Du, Jinfa; Chu, Chung K., Nucleosides and Nucleotides, 1998, vol. 17, # 1-3, p. 1 - 13
  作者：Du, Jinfa、Chu, Chung K.

  DOI：——

  日期：——
• [EN] NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZODIAZÉPINE COMME AGENTS PAM DE GABA A GAMMA1
  申请人：[en]F. HOFFMANN-LA ROCHE AG

  公开号：WO2023052312A1

  公开（公告）日：2023-04-06

  The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.